Chelsea Therapeutics posts 3Q loss
14th Nov 2006, 16:00 GMT
Chelsea Therapeutics International, a local biopharmaceutical development company, reports a third-quarter net loss of $2.1 million, or 11 cents per diluted share. In the same period last year, the company incurred a net loss of $1.7 million, or 14 cents per diluted share.
Chelsea Therapeutics posts 3Q loss related news:
- Repros Therapeutics 3Q Loss Widens — Financial News News from StratCenter.com
- Chelsea Therapeutics Reports Third Quarter 2006 Results — ArriveNet : Press Releases
- Chelsea Therapeutics Reports Q3 2006 Results — Operations-Related News from StratCenter.com
- PokerTek posts 3Q loss of $2.3M — Latest news from Charlotte Business Journal
- Regency posts larger 3Q loss — Latest news from Dallas Business Journal
- UGS Corp. posts wider 3Q loss — Latest news from Dallas Business Journal
- CHAD Therapeutics revenue down, loss up in 2Q — Latest news from Los Angeles Business from bizjournals
- Adherex posts wider 3Q loss on increased expenses — bizjournals.com Health Care:Industry Regulation headlines
- Kitty Hawk posts wider 3Q loss — bizjournals.com Travel:Airlines & Airports headlines
- Solexa Narrows 3Q Loss — Bio-Technology News from StratCenter.com
Latest news from Latest news from Charlotte Business Journal:
- MedCath completes public offering
- PokerTek posts 3Q loss of $2.3M
- Newell Rubbermaid to expand in Huntersville
- Bowater to record $200M impairment charge
- Cato 3Q income up 44%
- US LEC loss widens in third quarter
- NorthEast Medical unit seeks diagnostic center
- BofA, Aetna launch credit card
- Hospital Authority seeks to move nursing-home beds